XML 122 R50.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT INFORMATION (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Total revenues [1] $ 168,721 $ 110,748
Cost of revenues 36,593 25,688
Research and development expense (excluding stock-based compensation expense):    
Research and development 1,190,884 1,921,811
General and administrative expense (excluding share-based compensation expense) 2,553,459 2,367,821
Amortization 15,107 3,751
Stock-based compensation expense 3,560,509 2,413,375
Professional fees 966,815 574,598
Interest (income) expense, net (3,193) 38,835
Equity in net income from equity method investees (4,851)
Other income (139,420) (1,086,422)
Segment net loss (7,607,182) (4,648,709)
Adjustments and reconciling items
Consolidated net loss (7,607,182) (4,648,709)
Clinical Trials [Member]    
Research and development expense (excluding stock-based compensation expense):    
Research and development 87,492 80,569
HALO Design [Member]    
Research and development expense (excluding stock-based compensation expense):    
Research and development 534,527 336,870
SYNC Project [Member]    
Research and development expense (excluding stock-based compensation expense):    
Research and development 102,565
Other research and development [Member]    
Research and development expense (excluding stock-based compensation expense):    
Research and development [2] $ 66,300 $ 4,372
[1] Revenue concentrations are reflected in Note 9
[2] Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.